NCT02593487View on ClinicalTrials.gov

Effect of Rosuvastatin Therapy on HDL2 Level

PHASE4UnknownINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

June 30, 2017

Conditions
HyperlipemiaCoronary Heart Disease
Interventions
DRUG

Rosuvastatin 10mg/d group

rosuvastatin 10mg tablet,q.d. for 12 weeks.

DRUG

Rosuvastatin 20mg/d group

rosuvastatin 20mg tablet,q.d. for 12 weeks.

Trial Locations (1)

400042

Xu-kai Wang, Chongqing

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

OTHER